Figure 2.

Vβ usage at diagnosis and during treatment. (A) Percentages of Vβ family in CD8⁺CD57⁺ cells were calculated on total CD8⁺ cells, and Vβ skewing in severe aplastic anemia (SAA) patients was defined using the mean+3Standard Deviation (SD) of a given Vβ group in healthy donors. Relative expansion of each Vβ subgroup is shown in the bar graph. Patients were divided based on the absence or presence of expanded CD8⁺CD57⁺ cells, using the mean in healthy donors (13.3%). Skewing of one Vβ family is reported as an orange bar. (B) Progression-free survival rate of SAA patients with CD8⁺CD57⁺ cells ≤13.3% (n=7) or >13.3% (n=17) prior to treatment. Log-rank (Mantel-Cox) test was performed. (C) Vβ usage was performed in Patient 22 at diagnosis, at 10 days of treatment, and at 6 and 9 months (relapse). Perturbations during treatment and relapse are reported as percentage of positive CD8⁺CD57⁺ and Vβ2⁺ cells (left), or absolute lymphocyte and Vβ2 clone count (right).